Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 21 November, 2024
Author: Getaka|Social: Getaka Financial Services X (Earlier Twitter) Profile Getaka Financial Services LinkedIn Logo
Stock Ticker - BSE: 532660 | NSE: VIVIMEDLAB

Vivimed Labs Ltd: Intrinsic Value and Fundamental Analysis

Share Price and Basic Stock Data

Last Updated: November 16, 2024, 9:28 pm

Market Cap 41.0 Cr.
Current Price 4.95
High / Low/
Stock P/E
Book Value 0.66
Dividend Yield0.00 %
ROCE11.0 %
ROE268 %
Face Value 2.00
PEG Ratio0.00

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Vivimed Labs Ltd

Competitors of Vivimed Labs Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Gujarat Themis Biosyn Ltd 3,465 Cr. 318390/10865.7 20.50.21 %45.0 %33.8 % 1.00
Gujarat Terce Laboratories Ltd 59.8 Cr. 80.694.9/25.822.9 11.90.00 %9.72 %3.44 % 10.0
Gujarat Inject (Kerala) Ltd 28.0 Cr. 19.119.5/8.3536.3 6.640.00 %4.06 %3.33 % 10.0
Godavari Drugs Ltd 85.5 Cr. 114155/87.012.8 55.40.00 %12.7 %15.5 % 10.0
Glenmark Life Sciences Ltd 13,221 Cr. 1,0801,335/62031.2 2072.08 %28.1 %21.1 % 2.00
Industry Average19,460.76 Cr1,177.0554.20184.880.33%16.40%16.92%6.61

All Competitor Stocks of Vivimed Labs Ltd

Quarterly Result

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Sales278396554576150445637353441
Expenses3005554656462595461201364040
Operating Profit-22-1611-10-7-1-9-9-5-164-0-61
OPM %-8%-42%17%-19%-13%-2%-17%-21%-9%-444%-1%-18%3%
Other Income4210-010001020
Interest16910912109999111213
Depreciation174544544496555
Profit before tax-50-28-2-23-24-16-22-22-18-268-16-20-17
Tax %-1%-2%0%0%0%18%-0%0%0%-1%0%0%-3%
Net Profit-50-27-2-23-24-18-22-22-18-266-16-20-16
EPS in Rs-5.98-3.31-0.28-2.81-2.86-2.21-2.68-2.66-2.21-32.08-1.88-2.45-1.94

Last Updated: Unknown

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: Unknown

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales6681,1091,3511,3801,3461,4621,1861,3151,059861237187147
Expenses5389161,1391,1561,1111,0579711,1351,049830245374317
Operating Profit1301932122242344042151801032-8-187-169
OPM %20%17%16%16%17%28%18%14%1%4%-3%-100%-115%
Other Income312861181023810113
Interest28486786846882706156403644
Depreciation2759666661585667675618108110
Profit before tax789887781002868666-109-70-65-331-321
Tax %19%15%24%7%16%25%11%13%-0%3%4%-1%
Net Profit63846672842147657-109-72-68-329-318
EPS in Rs9.0610.418.208.9010.3326.419.446.95-13.16-8.67-8.16-39.62-38.35
Dividend Payout %7%6%7%0%0%2%4%0%0%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2012-20132013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-2023
YoY Net Profit Growth (%)33.33%-21.43%9.09%16.67%154.76%-64.49%-25.00%-291.23%33.94%5.56%-383.82%
Change in YoY Net Profit Growth (%)0.00%-54.76%30.52%7.58%138.10%-219.25%39.49%-266.23%325.17%-28.39%-389.38%

Vivimed Labs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2012-2013 to 2022-2023.

Growth

Compounded Sales Growth
10 Years:-20%
5 Years:-35%
3 Years:-44%
TTM:-20%
Compounded Profit Growth
10 Years:%
5 Years:%
3 Years:11%
TTM:86%
Stock Price CAGR
10 Years:-24%
5 Years:-17%
3 Years:-35%
1 Year:%
Return on Equity
10 Years:-2%
5 Years:-38%
3 Years:-72%
Last Year:-268%

Last Updated: Unknown

Balance Sheet

Last Updated: Unknown

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital14161616161617171717171717
Reserves32842747847950571888560249341534823160
Borrowings6957299581,0761,0151,0111,1491,2801,268326359379320
Other Liabilities263405406327519317343431432532543651714
Total Liabilities1,2991,5771,8581,8982,0552,0622,3942,3292,2101,2891,2661,0691,210
Fixed Assets5957098088138148791,0359651,045502520436522
CWIP82738909476651228960402121
Investments1003333386199199199192
Other Assets6958401,0119921,1441,1041,2901,239990529507414476
Total Assets1,2991,5771,8581,8982,0552,0622,3942,3292,2101,2891,2661,0691,210

Reserves and Borrowings Chart

Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity +90-1181401545821422805672835-24
Cash from Investing Activity +-170-291-107-190-68-164-89-196404-16-528
Cash from Financing Activity +67419-424135186-33872-1,015-10-34-6
Net Cash Flow-1211-842544-5-44-441-3-2

Free Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Free Cash Flow-565.00-536.00-746.00223.00233.00403.00214.00179.009.00-294.00-367.00-566.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days1211019487885085998646134150
Inventory Days268247249244294329411397396263573216
Days Payable170118106107981221542071793510093
Cash Conversion Cycle220230237224285258342288303274607273
Working Capital Days208161159146169151239161216190653588
ROCE %14%13%12%11%12%22%9%7%-3%-1%-3%-52%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Promoters28.57%28.57%28.57%28.57%21.98%20.96%20.96%20.96%20.94%20.94%20.94%20.94%
FIIs3.10%2.66%1.85%1.64%1.64%1.64%1.64%1.64%1.64%1.64%1.64%1.64%
Government0.12%0.12%0.12%0.12%0.12%0.12%0.12%0.12%0.12%0.12%0.12%0.12%
Public68.21%68.65%69.47%69.67%76.27%77.29%77.28%77.29%77.30%77.30%77.29%77.30%
No. of Shareholders37,98951,96350,92852,07453,11053,37652,39851,02650,68349,50349,03849,027

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
FaceValue2.002.002.002.002.00
Basic EPS (Rs.)-39.62-8.16-8.67-13.166.95
Diluted EPS (Rs.)-39.62-7.92-8.42-12.776.67
Cash EPS (Rs.)-26.55-5.95-1.98-5.0915.04
Book Value[Excl.RevalReserv]/Share (Rs.)0.1739.3547.4756.8570.35
Book Value[Incl.RevalReserv]/Share (Rs.)4.7543.9352.0561.4374.96
Revenue From Operations / Share (Rs.)22.5728.62103.90127.70159.37
PBDIT / Share (Rs.)-22.47-0.814.771.9724.25
PBIT / Share (Rs.)-35.55-3.02-1.93-6.1016.15
PBT / Share (Rs.)-39.88-7.82-8.43-13.208.00
Net Profit / Share (Rs.)-39.62-8.16-8.67-13.166.95
NP After MI And SOA / Share (Rs.)-39.62-8.16-8.67-13.166.95
PBDIT Margin (%)-99.59-2.864.581.5415.21
PBIT Margin (%)-157.53-10.56-1.85-4.7710.13
PBT Margin (%)-176.72-27.32-8.10-10.335.02
Net Profit Margin (%)-175.59-28.50-8.34-10.304.36
NP After MI And SOA Margin (%)-175.59-28.50-8.34-10.304.36
Return on Networth / Equity (%)-23087.35-20.73-18.26-23.149.88
Return on Capital Employeed (%)-52.25-2.80-1.68-3.519.25
Return On Assets (%)-33.24-5.34-5.57-4.932.46
Long Term Debt / Equity (X)43.790.180.140.990.73
Total Debt / Equity (X)266.031.100.641.891.30
Asset Turnover Ratio (%)0.160.180.120.160.14
Current Ratio (X)0.781.361.551.271.38
Quick Ratio (X)0.590.710.800.610.75
Inventory Turnover Ratio (X)1.170.570.240.370.31
Dividend Payout Ratio (NP) (%)0.000.000.000.00574.49
Dividend Payout Ratio (CP) (%)0.000.000.000.00265.44
Earning Retention Ratio (%)0.000.000.000.00-474.49
Cash Earning Retention Ratio (%)0.000.000.000.00-165.44
Interest Coverage Ratio (X)-5.19-0.170.730.272.97
Interest Coverage Ratio (Post Tax) (X)-8.15-0.70-0.33-0.851.85
Enterprise Value (Cr.)430.11471.51378.03898.62854.91
EV / Net Operating Revenue (X)2.301.990.430.840.65
EV / EBITDA (X)-2.31-69.449.5754.914.27
MarketCap / Net Operating Revenue (X)0.290.500.150.050.14
Retention Ratios (%)0.000.000.000.00-474.49
Price / BV (X)38.870.360.330.120.33
Price / Net Operating Revenue (X)0.290.500.150.050.14
EarningsYield-5.94-0.56-0.54-1.810.29

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Vivimed Labs Ltd as of November 21, 2024 is: 27.06

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of November 21, 2024, Vivimed Labs Ltd is Undervalued by 446.67% compared to the current share price 4.95

Default values used*: Default value of 15 for Stock P/E is used

Intrinsic Value of Vivimed Labs Ltd as of November 21, 2024 is: 14.08

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of November 21, 2024, Vivimed Labs Ltd is Undervalued by 184.44% compared to the current share price 4.95

Default values used*: Default value of 15 for Stock P/E is used

Last 5 Year EPS CAGR: -47.96%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
    1. The stock has a low average ROCE of 3.42%, which may not be favorable.
    2. The stock has a high average Working Capital Days of 253.42, which may not be favorable.
    3. The stock has a high average Cash Conversion Cycle of 295.08, which may not be favorable.
    4. The company has higher borrowings (812.69) compared to reserves (450.85), which may suggest financial risk.
    5. The company has not shown consistent growth in sales (162.15) and profit (-1.31).

    Stock Analysis

    • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Vivimed Labs Ltd:
      1. Net Profit Margin: -175.59%
        • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
      2. ROCE: -52.25% (Industry Average ROCE: 16.4%)
        • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
      3. ROE%: -23087.35% (Industry Average ROE: 16.92%)
        • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
      4. Interest Coverage Ratio (Post Tax): -8.15
        • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
      5. Quick Ratio: 0.59
        • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
      6. Stock P/E: 0 (Industry average Stock P/E: 54.2)
        • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
      7. Total Debt / Equity: 266.03
        • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
      The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
      Stock Rating:

    About the Company - Qualitative Analysis

    Vivimed Labs Ltd. is a Public Limited Listed company incorporated on 22/09/1988 and has its registered office in the State of Karnataka, India. Company’s Corporate Identification Number(CIN) is L02411KA1988PLC009465 and registration number is 009465. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 218.37 Cr. and Equity Capital is Rs. 16.58 Cr. for the Year ended 31/03/2022.
    INDUSTRYADDRESSCONTACT
    PharmaceuticalsPlot No. 78/A, Kolhar Industrial Area, Bidar Karnataka 585403yugandhar.kopparthi@vivimedlabs.com
    http://www.vivimedlabs.com
    Management
    NamePosition Held
    Mr. Sandeep VaralwarWhole Time Director
    Dr. Jamalapuram HarigopalChairman & Ind.Director
    Mr. Subhash VaralwarNon Executive Director
    Mr. Santosh VaralwarManaging Director
    Dr. Manohar Rao VaralwarWhole Time Director
    Ms. Aparna BidarkarIndependent Director

    FAQ

    What is the latest intrinsic value of Vivimed Labs Ltd?

    The latest intrinsic value of Vivimed Labs Ltd as on 19 November 2024 is ₹27.06, which is 446.67% higher than the current market price of ₹4.95.

    What is the Market Cap of Vivimed Labs Ltd?

    The Market Cap of Vivimed Labs Ltd is 41.0 Cr..

    What is the current Stock Price of Vivimed Labs Ltd as on 19 November 2024?

    The current stock price of Vivimed Labs Ltd as on 19 November 2024 is ₹4.95.

    What is the High / Low of Vivimed Labs Ltd stocks in FY 2024?

    In FY 2024, the High / Low of Vivimed Labs Ltd stocks is /.

    What is the Stock P/E of Vivimed Labs Ltd?

    The Stock P/E of Vivimed Labs Ltd is .

    What is the Book Value of Vivimed Labs Ltd?

    The Book Value of Vivimed Labs Ltd is 0.66.

    What is the Dividend Yield of Vivimed Labs Ltd?

    The Dividend Yield of Vivimed Labs Ltd is 0.00 %.

    What is the ROCE of Vivimed Labs Ltd?

    The ROCE of Vivimed Labs Ltd is 11.0 %.

    What is the ROE of Vivimed Labs Ltd?

    The ROE of Vivimed Labs Ltd is 268 %.

    What is the Face Value of Vivimed Labs Ltd?

    The Face Value of Vivimed Labs Ltd is 2.00.

    About the Author

    Author Avatar
    Getaka

    Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

    Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Vivimed Labs Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE